HEARTio

AI-powered diagnostics for identifying heart abnormalities in emergency settings

Website: https://heartio.ai/

Cover Block

PUBLIC

Field Value
Name HEARTio
Tagline AI-powered diagnostics for identifying heart abnormalities in emergency settings
Headquarters Pittsburgh, United States
Founded 2018
Stage Seed
Business Model B2B
Industry Healthtech
Technology AI / Machine Learning
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (3+)
Funding Label Seed
Total Disclosed ~$1,500,000

Links

PUBLIC

Executive Summary

PUBLIC

HEARTio is a Pittsburgh-based clinical-AI company applying machine learning to electrocardiogram (ECG) interpretation, with the stated goal of helping emergency providers detect coronary artery disease faster than current standard-of-care reads [Crunchbase][Forbes]. The company was founded in 2018 by three University of Pittsburgh alumni, Adam Butchy, Utkars Jain, and Michael Leasure, who were named to the Forbes 30 Under 30 Healthcare list in 2024 [technical.ly][University of Pittsburgh]. Its lead product, an algorithm marketed as ECGio, is positioned to triage chest-pain presentations in the emergency department, a setting where minutes of diagnostic delay translate directly into myocardial damage [Forbes]. The product is not yet FDA-cleared, though Forbes reports a validation study showed promising algorithmic performance [Forbes]. To date the company has raised approximately $1.5 million through a mix of angel checks, foundation grants (including the Richard King Mellon Foundation), and competition winnings, a capital-light path typical of early Pittsburgh healthtech [Dealroom.co]. The business is structured B2B, with hospitals and emergency departments as the eventual buyers, though commercial deployment remains gated by regulatory clearance. Over the next 12 to 18 months, the salient questions are FDA submission progress, the depth and design of the validation cohort, and whether HEARTio can convert academic and foundation support into a priced Series A from a healthtech-specialist investor.

Data Accuracy: GREEN -- Confirmed by Crunchbase, Forbes, technical.ly, University of Pittsburgh, and Dealroom.co.

Taxonomy Snapshot

Axis Value
Stage Seed
Business Model B2B
Industry / Vertical Healthtech / Cardiac Diagnostics
Technology Type AI / Machine Learning
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (3+)
Funding ~$1.5M disclosed (Seed)

Company Overview

PUBLIC

HEARTio (the legal entity is registered as Heart Input Output, Inc., per its Crunchbase profile) was founded in 2018 in Pittsburgh by Adam Butchy, Utkars Jain, and Michael Leasure, three University of Pittsburgh alumni who built the original ECG-interpretation work out of academic research at Pitt [Crunchbase][PitchBook][University of Pittsburgh]. The founding thesis, as the company describes it on its own site, is that cardiac diagnostics should be "fast, accurate, and accessible" through AI applied to ECG signal data [HEARTio]. In practice that has meant focusing first on the emergency-department workflow, where chest-pain triage volume is high and where a faster read on coronary artery disease has the most direct clinical and economic value.

The company has progressed along the standard university-spinout path: an early algorithm (ECGio) developed and validated in academic settings, foundation and competition funding to bridge the pre-clearance phase, and a small core team supplemented by clinical and engineering advisors. Reported milestones include the publication of validation work supporting the algorithm's diagnostic performance, foundation backing from the Richard King Mellon Foundation, and the founders' selection to the Forbes 30 Under 30 Healthcare list in 2024, which generated a wave of regional press [Forbes][technical.ly][University of Pittsburgh]. The company remains headquartered in Pittsburgh, and LinkedIn lists 437 followers on its company page, consistent with a small, pre-commercial team [LinkedIn].

Data Accuracy: GREEN -- Confirmed by Crunchbase, PitchBook, Forbes, and the University of Pittsburgh.

Product and Technology

MIXED

HEARTio's core product is ECGio [PUBLIC], an algorithm that analyzes 12-lead electrocardiogram data to flag patterns associated with coronary artery disease, with the stated objective of accelerating diagnostic decision-making in emergency settings [Forbes][Crunchbase]. Forbes describes the product as "developing an algorithm called ECGio to help doctors detect coronary artery disease faster" and notes that a validation study found the algorithm able to identify disease patterns, though the system is "not yet FDA-cleared" [Forbes]. The company's own marketing language positions HEARTio as "smarter cardiac triage" and emphasizes accessibility of AI-powered diagnostics [HEARTio][LinkedIn].

Mechanically, the product appears to ingest standard ECG output and produce a probability or classification output that supplements the physician's read, rather than replacing it. This is the regulatory-friendly architecture used by most current AI-ECG entrants because it slots into existing clinical workflow as decision support rather than autonomous diagnosis. The specifics of model architecture, training-set size, and prospective validation design are not disclosed in public sources, and investors should request the validation manuscript and any pre-submission FDA correspondence directly.

On deployment, HEARTio has not publicly named hospital customers or integration partners, and there are no open engineering roles surfaced on major ATS hosts at the time of this review, which is consistent with a small, pre-commercial team focused on regulatory submission rather than scaled go-to-market. The technology stack and any cloud or on-prem deployment model is not publicly documented.

Data Accuracy: YELLOW -- Product purpose confirmed by Forbes and Crunchbase; technical and deployment specifics not publicly available.

Market Research and Opportunity

PUBLIC

AI-assisted ECG interpretation sits at the intersection of two structurally growing markets: cardiovascular diagnostics, which remains the single largest disease-burden category in the developed world, and clinical decision-support software, which has accelerated since the FDA began clearing algorithmic devices under its Software as a Medical Device pathway. The cited research base for HEARTio specifically is thin, so the framing here relies on adjacent public reporting and disclosed company facts rather than a bespoke TAM build.

Demand drivers are concrete. Emergency departments in the United States see roughly seven million chest-pain presentations annually according to widely cited CDC ambulatory care data, the majority of which are ruled out for acute coronary syndrome only after extended observation, repeat troponin testing, and downstream imaging. Any tool that meaningfully improves the negative predictive value of an early ECG read has direct economic value to the hospital (shorter length of stay, fewer admissions) and to the payer. This is the wedge HEARTio is targeting, per its own positioning around "smarter cardiac triage" [HEARTio][LinkedIn].

Adjacent and substitute markets matter for competitive context. The closest substitutes are traditional high-sensitivity troponin assays (already standard of care), incumbent ECG-machine vendors' built-in interpretation algorithms (GE, Philips, Hillrom), and a growing cohort of AI-ECG startups and academic spinouts targeting either rhythm disorders, structural heart disease, or ischemia. On the regulatory side, the FDA has cleared a steadily increasing number of AI/ML-enabled cardiology devices in recent years, which is a tailwind for category legitimacy but also a signal that the bar for novel clearances is rising as the field matures.

Market signal Value Source
HEARTio disclosed funding ~$1.5M [Dealroom.co]
HEARTio LinkedIn followers 437 [LinkedIn]
Founding year 2018 [PitchBook]

HEARTio is operating in a market with strong structural tailwinds and a clear clinical pain point, but the company itself remains pre-clearance and pre-revenue based on public disclosure. The opportunity is real; execution against the FDA timeline is what converts it.

Data Accuracy: YELLOW -- Company facts confirmed by Dealroom.co, LinkedIn, and PitchBook; market context drawn from analogous public reporting rather than a HEARTio-specific third-party study.

Competitive Landscape

MIXED

HEARTio competes in the AI-ECG interpretation segment, where the named competitive set is dominated by larger, better-capitalized companies that have already cleared FDA pathways for adjacent indications.

The competitive map breaks into three layers. The first is the incumbent ECG-device vendors (GE Healthcare, Philips, Hillrom/Baxter) whose machines ship with bundled interpretation software and who already own the hardware footprint inside emergency departments. Their advantage is distribution and the data exhaust from millions of installed devices; their weakness is that legacy interpretation algorithms are widely regarded by cardiologists as conservative and prone to over-flagging. The second layer is the AI-native challengers, most notably a cohort of well-funded startups that have raised tens to hundreds of millions and have FDA clearances for specific indications such as low ejection fraction, atrial fibrillation screening, and hyperkalemia. The third is academic and hospital-system spinouts, the cohort HEARTio most resembles in capital base and origin story, where differentiation comes from a specific clinical indication (coronary artery disease detection from ECG, in HEARTio's case) and from clinician-network credibility rather than capital firepower.

Where HEARTio has a defensible edge today, it is narrow but real: a focused indication (CAD detection in the ED), a Pittsburgh clinical-research base that includes Pitt and UPMC, and a founding team with academic credibility (the Forbes 30 Under 30 nod is more than vanity, it is a fundraising and recruiting asset) [Forbes][University of Pittsburgh]. That edge is perishable. The moat is not the algorithm itself, which competitors can and will replicate, but the specific validation dataset and the FDA clearance once obtained. Until the clearance lands, the edge is a research result, not a regulated product.

Where HEARTio is most exposed is on capital and clearance timeline. Competitors with $50M+ war chests can run larger prospective trials, hire dedicated regulatory affairs teams, and pursue parallel indications. The plausible 18-month scenario splits two ways. HEARTio wins if it secures FDA De Novo or 510(k) clearance for ECGio in CAD detection and pairs it with a credible Series A from a healthtech-specialist fund, which would let it convert academic credibility into hospital pilots. HEARTio loses ground if a better-capitalized AI-ECG company files first for an overlapping indication, which would compress the differentiation window and force HEARTio into either a niche or an acquisition conversation.

Data Accuracy: ORANGE -- HEARTio's own positioning confirmed by Forbes and Crunchbase; the named competitor set is analyst context drawn from public knowledge of the AI-ECG category, not from sources that specifically benchmark HEARTio.

Opportunity

PUBLIC

If HEARTio executes, the prize is becoming the default AI second-read for ECG-based ischemia detection in U.S. emergency departments, a workflow position that is sticky, recurring, and reimbursable.

The headline opportunity. The single largest plausible outcome for HEARTio is to become the clinical-AI standard for ED chest-pain triage, the same way that high-sensitivity troponin became the standard biomarker layer over the past decade. The cited evidence makes this reachable rather than aspirational for three reasons: the clinical problem (faster, more accurate CAD detection) is universally acknowledged by emergency physicians and cardiologists, the input data (12-lead ECG) is already captured on every patient, and the regulatory pathway for AI-ECG interpretation has been opened by prior FDA clearances of analogous algorithms. Forbes' note that the validation study "found the algorithm is able to" perform meaningfully on the target indication is the foundational signal [Forbes]. Foundation backing from the Richard King Mellon Foundation indicates that a credible regional non-dilutive funder has done diligence on the science [Dealroom.co].

Growth scenarios.

Scenario What happens Catalyst Why it's plausible
Clearance and pilot FDA clears ECGio for CAD detection, HEARTio lands paid pilots in 3-5 academic medical centers Successful 510(k) or De Novo submission, anchored by UPMC or another Pitt-affiliated system Validation study results already reported [Forbes]; regional clinical network through Pitt [University of Pittsburgh]
Embedded distribution HEARTio licenses ECGio to an incumbent ECG-machine vendor or EHR for embedded distribution OEM partnership with a cardiology-equipment vendor or Epic/Cerner integration Capital-light path consistent with the ~$1.5M raised to date [Dealroom.co]; pattern matches prior AI-ECG licensing deals in the category
Strategic acquisition A larger cardiology-AI or device company acquires HEARTio for the ECGio asset and clearance Post-clearance acquisition by a strategic seeking a CAD indication The category has seen consolidation as larger players round out indication portfolios

What compounding looks like. The flywheel in clinical AI is data and clearance. Each cleared indication generates real-world performance data, which strengthens the next submission, which expands the addressable workflow, which deepens the dataset. For HEARTio specifically, a CAD-detection clearance would give the company prospective deployment data that could support label expansions (other ischemic patterns, risk stratification, post-discharge monitoring) without rebuilding the underlying signal-processing stack. Distribution lock-in compounds separately: once an algorithm is integrated into ED workflow and validated against a hospital's own patient population, switching costs are meaningful, both clinically and from a compliance standpoint.

The size of the win. Comparable public and private benchmarks in AI-ECG suggest the category can support multi-hundred-million-dollar outcomes for companies that secure FDA clearance and scale hospital deployment, with the largest peers having raised at unicorn or near-unicorn valuations on the strength of cleared indications and named health-system customers. Translated to HEARTio: in the clearance-plus-pilot scenario, a credibly priced Series A in the $10-25M range becomes plausible, and in the acquisition scenario, a strategic exit anchored on the cleared CAD asset is the most likely path to liquidity (scenario, not a forecast). The upside case is meaningful; it is also tightly conditional on the FDA timeline and on raising enough capital to run the pivotal validation work.

Data Accuracy: YELLOW -- HEARTio-specific facts confirmed by Forbes, Dealroom.co, and University of Pittsburgh; scenario framing and comparable valuations are analyst extrapolation.

Sources

PUBLIC

  1. [Crunchbase] HEARTio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/heart-input-output-inc

  2. [Forbes] HEARTio profile | https://www.forbes.com/profile/heartio/

  3. [HEARTio] Company website | https://heartio.ai/

  4. [technical.ly] HEARTio's founders got a Forbes 30 Under 30 nod. Here's what's next for the Pittsburgh healthtech company | https://technical.ly/startups/heartio-forbes-30-under-ecgio/

  5. [LinkedIn] HEARTio company page | https://www.linkedin.com/company/heartio

  6. [PitchBook] HEARTio 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/265965-31

  7. [Dealroom.co] HeartIO company information, funding & investors | https://app.dealroom.co/companies/heartio

  8. [University of Pittsburgh] 3 student founders of a Pitt health care startup were listed on the Forbes 30 Under 30 list | https://www.pittwire.pitt.edu/pittwire/accolades-honors/heartio-forbes-30-under-30

  9. [LinkedIn] Utkars Jain, PhD - HEARTio | https://www.linkedin.com/in/utkars-jain/

Articles about HEARTio

View on Startuply.vc